By Rosemary Frei, MSc The diagnosis of systemic lupus erythematosus (SLE) is challenging, because of the heterogeneous nature of this disease. Early disease is especially challenging because patients often present with severe but uncharacteristic features. A team of rheumatologists has created a diagnostic algorithm based on the differential diagnosis of SLE (Bertsias GK, et al. Nat Rev Rheumatol. 2013 July 9 [Epub ahead of print]).
Survey Shows Significant Disease Burden on Patients with Lupus and Limitations of Current Treatment Regimens
Corticosteroids associated with most side effects, patient dissatisfaction By Rosemary Frei, MSc An independent survey conducted in 2012 and recently published of patients with systemic lupus erythematosus (SLE) and their physicians confirms the significant burden SLE confers on patients in quality of life and work productivity and the limitations of currently available drug regimens in relieving the considerable impairment (Strand V, et al. Lupus. 2013;22:819-826). Despite the limitations of the treatment regimens in controlling disease activity, patients and physicians reported overall satisfaction with current treatment regimens.
Few studies have addressed whether certain clinical and laboratory characteristics predict partial remission (PR) in patients with ankylosing spondylitis who are taking the anti–tumor necrosis factor (TNF) inhibitors infliximab (Remicade), etanercept (Enbrel), or adalimumab (Humira). A recent study has investigated the possibility of achieving PR in patients with ankylosing spondylitis who were treated with 1 of these 3 agents in a real-world clinical practice setting.
By Alice Goodman Madrid, Spain—Abatacept (Orencia) and adalimumab (Humira) were similarly cost-effective for the treatment of adults with rheumatoid arthritis (RA) who had an inadequate response to methotrexate, according to a cost-effectiveness subanalysis of the AMPLE (Abatacept Versus Adalimumab Comparison in Biologic Naive RA Subjects with Background Methotrexate) trial.
Several studies have suggested a possible link between systemic lupus erythematosus (SLE) and vitamin D insufficiency. In a new study of patients with SLE who had low levels of vitamin D, researchers investigated whether vitamin D supplementation was associated with improvements in disease activity.
Quality indicators (QIs) for osteoarthritis (OA) care have been developed to measure QI “pass rates” using medical records or healthcare provider questionnaires. However, the patient perspective of pass rates for QIs in OA has not been investigated. A team of experts has developed the first instrument for patient-reported quality of OA care to assess QI pass rates as reported by patients with OA.
By Phoebe Starr Madrid, Spain—Apremilast, a novel oral inhibitor of phosphodiesterase 4, achieved sustained improvement in the signs and symptoms of psoriatic arthritis, physical function, and skin improvement in the longer-term follow-up of 52 weeks in the PALACE 1 trial, according to results reported for the first time at the 2013 European League Against Rheumatism (EULAR) annual meeting.
Ilaris (Canakinumab) Receives a New Indication for the Treatment of Systemic Juvenile Idiopathic Arthritis
By Lisa A. Raedler, PhD, RPh Systemic juvenile idiopathic arthritis (SJIA) is a rare inflammatory disease, affecting approximately 10% of children diagnosed with juvenile idiopathic arthritis in the United States.1,2 The classic symptoms of SJIA include pain in the small joints of the hands, wrists, knees, and ankles; rash; and a high, spiking fever of ≥103°F that can last for weeks to months.3 By definition, SJIA can present at any point until the age of 16 years. However, a long-term outcomes study found that the median age at diagnosis of SJIA was 4 years.4 The distribution of the disease by sex is roughly equal.
by Alice Goodman Madrid, Spain—Patients with active ankylosing spondylitis who achieve stable disease with anti–tumor necrosis factor (TNF) agents may be able to maintain low disease activity for as long as 2 years after dose reduction of an anti-TNF agent. A small observational cohort study showed that more than 40% of patients who had their doses of an anti-TNF agent reduced substantially still had low disease activity at 2 years.
By Phoebe Starr Madrid, Spain—It is well known that patients with rheumatoid arthritis (RA) have a greater frequency of depression than the general population. A study presented at the 2013 European League Against Rheumatism (EULAR) annual meeting showed that depression in patients with early RA was the strongest predictor of early retirement, even stronger than disease activity level, response to RA therapy, work-related stress, or comorbid conditions. These findings underscore the need for rheumatologists to ask patients about their mood and to refer them for help if they exhibit signs or symptoms of depression.
Page 1 of 3
Results 1 - 10 of 22
Results 1 - 10 of 22